Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
INOVIO PHARMACEUTICALS, INC. (INO)
|
Add to portfolio |
|
|
|
| Price: |
$5.20
| | Metrics |
| OS: |
268.1
|
M
| |
-99
|
% ROE
|
| Market cap: |
$1.39
|
B
| |
-141
|
% ROIC
|
|
Net cash:
|
$178
|
M
| |
$0.66
|
per share
|
|
EV:
|
$1.22
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($173)
|
M
| |
|
|
| EPS |
($0.67)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 10.3 | 1.8 | 7.4 | 4.1 | 30.5 | 42.2 | 35.4 | 40.6 |
| Revenue growth | 478.2% | -76.1% | 80.2% | -86.5% | -27.8% | 19.4% | -12.8% | 288.0% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 10.3 | 1.8 | 7.4 | 4.1 | 30.5 | 42.2 | 35.4 | 40.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 187.7 | 249.2 | 94.2 | 88.0 | 95.3 | 98.6 | 88.7 | 57.8 |
| General and administrative | 90.2 | 53.8 | 37.2 | 27.2 | 29.3 | 28.3 | 23.9 | 18.1 |
| EBITA | -269.2 | -301.1 | -124.0 | -110.0 | -92.8 | -83.0 | -76.0 | -35.1 |
| EBITA margin | -2623.6% | -16967.5% | -1673.1% | -2676.2% | -304.6% | -196.6% | -214.9% | -86.6% |
| Amortization of intangibles | 0.5 | 0.5 | 0.5 | 1.1 | 1.2 | 1.6 | 1.4 | 0.9 |
| EBIT | -269.7 | -301.7 | -124.5 | -111.1 | -94.1 | -84.6 | -77.4 | -36.0 |
| EBIT margin | -2628.5% | -16996.8% | -1680.5% | -2702.1% | -308.7% | -200.5% | -218.8% | -88.7% |
| Pre-tax income | -277.7 | -303.2 | -162.9 | -120.8 | -94.8 | -88.2 | -73.7 | -31.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | -0.3 | 2.2 | 0.0 | 0.0 | -2.1 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.2% | | 0.0% | 0.0% | 6.7% |
| Net income | -279.8 | -303.7 | -166.4 | -119.4 | -97.0 | -88.2 | -73.7 | -29.2 |
| Net margin | -2726.7% | -17109.9% | -2245.4% | -2902.8% | -318.1% | -208.9% | -208.5% | -71.9% |
| |
| Diluted EPS | ($1.17) | ($1.45) | ($1.07) | ($1.21) | ($1.05) | ($1.08) | ($1.01) | ($0.43) |
| Shares outstanding (diluted) | 238.6 | 208.8 | 155.1 | 98.7 | 92.5 | 81.9 | 73.2 | 68.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|